Editas Medicine, Inc.EDITEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 9.60% | 7.8M | — | 2024-01-24 |
| The Vanguard Group | 8.09% | 6.7M | flat | 2024-11-12 |
| Deep Track Capital, LP | 6.70% | 5.5M | ▲ +1.19pp | 2024-02-14 |
| STATE STREET CORPORATION | 3.00% | 2.5M | ▼ -2.58pp | 2024-10-17 |
Insider Transactions
Net 90d: −$13.4K · buys $0 / sells $13.4KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-03 | Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | Sell (open market) | 749 | $2.02 | $1.5K |
| 2026-03-03 | O'Neill Gilmore Neil | CEO | Sell (open market) | 5.4K | $2.02 | $10.9K |
| 2026-03-03 | Amy Parison | SVP, Chief Financial Officer | Sell (open market) | 474 | $2.02 | $957 |
1–3 of 3